|
|
Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China |
Rui Yu, Rong Fan, Jinlin Hou() |
Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China |
|
|
Abstract Chronic hepatitis B is a major health problem in China. The universal vaccination program since 1992 has changed the epidemiology of hepatitis B virus infection in China from highly to moderately endemic. The most prevalent hepatitis B virus strains in China are genotypes B and C, whereas those in western provinces are genotypes D and C/D hybrid. Chronic hepatitis B poses a heavy burden to the society in China. Different treatment strategies have been explored to improve patient outcomes in a cost-effective manner. However, antiviral drugs with a low genetic barrier to resistance are still extensively used because of the generally low income and limited resources in China. Individualized antiviral therapy is closely associated with translational medicine, which utilizes information from studies on genomics, immune biomarkers, and fibrosis. The results of these studies are crucial in further improving treatment outcomes.
|
Keywords
chronic hepatitis B
epidemiology
prevention
treatment
|
Corresponding Author(s):
Jinlin Hou
|
Issue Date: 21 May 2014
|
|
1 |
World Health Organization. Hepatitis B. (Revised July 2013). [2010-30]
|
2 |
D Ganem, AM Prince. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004; 350(11): 1118–1129
https://doi.org/10.1056/NEJMra031087
pmid: 15014185
|
3 |
HL Chan, JJ Sung. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26(2): 153–161
https://doi.org/10.1055/s-2006-939753
pmid: 16673293
|
4 |
X Liang, S Bi, W Yang, L Wang, G Cui, F Cui, Y Zhang, J Liu, X Gong, Y Chen, F Wang, H Zheng, F Wang, J Guo, Z Jia, J Ma, H Wang, H Luo, L Li, S Jin, SC Hadler, Y Wang. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27(47): 6550–6557
https://doi.org/10.1016/j.vaccine.2009.08.048
pmid: 19729084
|
5 |
S Schaefer. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005; 12(2): 111–124
https://doi.org/10.1111/j.1365-2893.2005.00584.x
pmid: 15720525
|
6 |
G Zeng, Z Wang, S Wen, J Jiang, L Wang, J Cheng, D Tan, F Xiao, S Ma, W Li, K Luo, NV Naoumov, J Hou. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat 2005; 12(6): 609–617
https://doi.org/10.1111/j.1365-2893.2005.00657.x
pmid: 16255762
|
7 |
Z Wang, Z Liu, G Zeng, S Wen, Y Qi, S Ma, NV Naoumov, J Hou. A new intertype recombinant between genotypes C and D of hepatitis B virus identified in China. J Gen Virol 2005; 86(Pt 4): 985–990
https://doi.org/10.1099/vir.0.80771-0
pmid: 15784891
|
8 |
B Zhou, L Xiao, Z Wang, ET Chang, J Chen, J Hou. Geographical and ethnic distribution of the HBV C/D recombinant on the Qinghai-Tibet Plateau. PLoS One 2011; 6(4): e18708
https://doi.org/10.1371/journal.pone.0018708
pmid: 21494570
|
9 |
B Zhou, Z Wang, J Yang, J Sun, H Li, Y Tanaka, M Mizokami, J Hou. Novel evidence of HBV recombination in family cluster infections in western China. PLoS One 2012; 7(6): e38241
https://doi.org/10.1371/journal.pone.0038241
pmid: 22675528
|
10 |
CJ Chen, HI Yang, J Su, CL Jen, SL You, SN Lu, GT Huang, UH Iloeje; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295(1): 65–73
https://doi.org/10.1001/jama.295.1.65
pmid: 16391218
|
11 |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57(1): 167–185
pmid: 22436845
|
12 |
YF Liaw, JH Kao, T Piratvisuth, H Chan, RN Chien, CJ Liu, E Gane, S Locarnini, SG Lim, KH Han, D Amarapurkar, G Cooksley, W Jafri, R Mohamed, JL Hou, WL Chuang, L Lesmana, J Sollano, DJ Suh, M Omata. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International 2012; 6(3): 531–561
https://doi.org/10.1007/s12072-012-9365-4
|
13 |
AS Lok, BJ McMahon. Chronic hepatitis B: update 2009. Hepatology 2009; 50(3): 661–662
https://doi.org/10.1002/hep.23190
pmid: 19714720
|
14 |
MJ Sonneveld, BE Hansen, T Piratvisuth, JD Jia, S Zeuzem, E Gane, YF Liaw, Q Xie, EJ Heathcote, HL Chan, HL Janssen. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58(3): 872–880
https://doi.org/10.1002/hep.26436
pmid: 23553752
|
15 |
J Hou, H Ma, J Sun, Q Xie, Y Xie, Y Sun, H Wang, G Shi, M Wan, J Niu, Q Ning, Y Yu, Y Zhao. Response guided peginterferon alfa-2a (PegIFN alfa-2a) therapy in patients with HBeAg-positive chronic hepatitis B (CHB). J Hepatol 2014[Epub ahead of print] (abstract)
|
16 |
V Rijckborst, BE Hansen, Y Cakaloglu, P Ferenci, F Tabak, M Akdogan, K Simon, US Akarca, R Flisiak, E Verhey, AJ Van Vuuren, CA Boucher, MJ ter Borg, HL Janssen. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52(2): 454–461
https://doi.org/10.1002/hep.23722
pmid: 20683945
|
17 |
Q Ning, M Han, Y Sun, JJ Jiang, D Tan, J Hou, H Tang, JF Sheng, M Jiang. Patients with HBeAg-positive chronic hepatitis B (CHB) with a maintained virological response to entecavir achieved HBsAg clearance when switched to peginterferon alfa-2a therapy (the OSST study). Hepatology 2011; 54(Suppl): 1010–1A
|
18 |
HL Chan. Peginterferon therapy for chronic hepatitis B: one size fits all? Gut 2013; 62(2): 185–187
https://doi.org/10.1136/gutjnl-2012-303291
pmid: 22942237
|
19 |
DJ Tenney, KA Pokornowski, RE Rose, CJ Baldick, BJ Eggers, J Fang, MJ Wichroski, UA Diva, D Xu, RB Wilber, H Brett-Smith, UH Iloeje. 20 entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 2009; 50(Suppl): S10
https://doi.org/10.1016/S0168-8278(09)60022-2
|
20 |
O Yokosuka, K Takaguchi, S Fujioka, M Shindo, K Chayama, H Kobashi, N Hayashi, C Sato, K Kiyosawa, K Tanikawa, H Ishikawa, N Masaki, T Seriu, M Omata. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010; 52(6): 791–799
https://doi.org/10.1016/j.jhep.2009.12.036
pmid: 20409606
|
21 |
EJGP Marcellin, N Tsai, R Flisiak, SGJ Petersen, IA Kotzev, JF Flaherty, P Dinh, A Gaggar, KM Kitrinos, M Subramanian, JG McHutchison, J George, M Buti. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2013; 58(S1): 649A
|
22 |
P Marcellin, E Gane, M Buti, N Afdhal, W Sievert, IM Jacobson, MK Washington, G Germanidis, JF Flaherty, RA Schall, JD Bornstein, KM Kitrinos, GM Subramanian, JG McHutchison, EJ Heathcote. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381(9865): 468–475
https://doi.org/10.1016/S0140-6736(12)61425-1
pmid: 23234725
|
23 |
AS Lok, CL Lai, N Leung, GB Yao, ZY Cui, ER Schiff, JL Dienstag, EJ Heathcote, NR Little, DA Griffiths, SD Gardner, M Castiglia. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125(6): 1714–1722
https://doi.org/10.1053/j.gastro.2003.09.033
pmid: 14724824
|
24 |
SJ Hadziyannis, NC Tassopoulos, EJ Heathcote, TT Chang, G Kitis, M Rizzetto, P Marcellin, SG Lim, Z Goodman, J Ma, CL Brosgart, K Borroto-Esoda, S Arterburn, Chuck SL; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131(6): 1743–1751
https://doi.org/10.1053/j.gastro.2006.09.020
pmid: 17087951
|
25 |
MF Yuen, E Sablon, CK Hui, HJ Yuan, H Decraemer, CL Lai. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34(4): 785–791
|
26 |
HB Chae, HW Hann, CK Hui, HJ Yuan, H Decraemer, CL Lai. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085–4090
pmid: 17696226
|
27 |
YF Liaw, E Gane, N Leung, S Zeuzem, Y Wang, CL Lai, EJ Heathcote, M Manns, N Bzowej, J Niu, SH Han, SG Hwang, Y Cakaloglu, MJ Tong, G Papatheodoridis, Y Chen, NA Brown, E Albanis, K Galil, NV Naoumov; GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136(2): 486–495
https://doi.org/10.1053/j.gastro.2008.10.026
pmid: 19027013
|
28 |
HW Hann. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opin Pharmacother 2010; 11(13): 2243–2249
https://doi.org/10.1517/14656566.2010.512437
pmid: 20698726
|
29 |
JJ Sung, JY Lai, S Zeuzem, WC Chow, EJ Heathcote, RP Perrillo, CL Brosgart, MA Woessner, SA Scott, DF Gray, SD Gardner. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48(5): 728–735
https://doi.org/10.1016/j.jhep.2007.12.026
pmid: 18329126
|
30 |
CK Hui, HY Zhang, S Bowden, S Locarnini, JM Luk, KW Leung, YH Yueng, A Wong, F Rousseau, KY Yuen, NN Naoumov, GK Lau. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008; 48(5): 714–720
https://doi.org/10.1016/j.jhep.2007.10.013
pmid: 18207280
|
31 |
AS1 Lok, H Trinh, G Carosi, US Akarca, A Gadano, F Habersetzer, W Sievert, D Wong, M Lovegren, D Cohen, C Llamoso. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012; 143(3): 619–28 e1
pmid: 22643350
|
32 |
NA Terrault. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009; 49(5 Suppl): S122–S128
https://doi.org/10.1002/hep.22921
pmid: 19399796
|
33 |
EB Keeffe, S Zeuzem, RS Koff, DT Dieterich, R Esteban-Mur, EJ Gane, IM Jacobson, SG Lim, N Naoumov, P Marcellin, T Piratvisuth, F Zoulim. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5(8): 890–897
https://doi.org/10.1016/j.cgh.2007.05.004
pmid: 17632041
|
34 |
J Sun, Q Xie, D Tan, Q Ning, J Niu, X Bai, R Fan, S Chen, J Cheng, Y Yu, H Wang, M Xu, G Shi, M Wan, X Chen, H Tang, J Sheng, X Dou, J Shi, H Ren, M Wang, H Zhang, Z Gao, C Chen, H Ma, J Jia, J Hou. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 2014; 59(4): 1283–1292
pmid: 24382690
|
35 |
MG Peters, Hw Hann Hw, P Martin, EJ Heathcote, P Buggisch, R Rubin, M Bourliere, K Kowdley, C Trepo, Df Gray Df, M Sullivan, K Kleber, R Ebrahimi, S Xiong, CL Brosgart. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126(1): 91–101
https://doi.org/10.1053/j.gastro.2003.10.051
pmid: 14699491
|
36 |
I Rapti, E Dimou, P Mitsoula, SJ Hadziyannis. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45(2): 307–313
https://doi.org/10.1002/hep.21534
pmid: 17256746
|
37 |
P Lampertico, M Viganò, E Manenti, M Iavarone, E Sablon, M Colombo. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133(5): 1445–1451
https://doi.org/10.1053/j.gastro.2007.08.079
pmid: 17983801
|
38 |
H Yang, X Qi, A Sabogal, M Miller, S Xiong, WE Delaney 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10(5): 625–633
pmid: 16152756
|
39 |
O Lada, Y Benhamou, A Cahour, C Katlama, T Poynard, V Thibault. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9(3): 353–363
pmid: 15259898
|
40 |
J Sun, JL Hou, Q Xie, XH Li, JM Zhang, YM Wang, H Wang, JY Lai, SJ Chen, JD Jia, JF Sheng, HL Chan, JF Wang, MK Li, M Jiang, M Popescu, JJ Sung. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther 2011; 34(4): 424–431
https://doi.org/10.1111/j.1365-2036.2011.04750.x
pmid: 21692822
|
41 |
T Berg, P Marcellin, F Zoulim, B Moller, H Trinh, S Chan, E Suarez, F Lavocat, A Snow-Lampart, D Frederick, J Sorbel, K Borroto-Esoda, D Oldach, F Rousseau. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139(4): 1207–1217, e3
https://doi.org/10.1053/j.gastro.2010.06.053
pmid: 20600025
|
42 |
M Sherman, C Yurdaydin, J Sollano, M Silva, YF Liaw, J Cianciara, A Boron-Kaczmarska, P Martin, Z Goodman, R Colonno, A Cross, G Denisky, B Kreter, R Hindes; AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130(7): 2039–2049
https://doi.org/10.1053/j.gastro.2006.04.007
pmid: 16762627
|
43 |
M Sherman, C Yurdaydin, H Simsek, M Silva, YF Liaw, VK Rustgi, H Sette, N Tsai, DJ Tenney, J Vaughan, B Kreter, R Hindes; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48(1): 99–108
https://doi.org/10.1002/hep.22323
pmid: 18537189
|
44 |
J Petersen, V Ratziu, M Buti, HL Janssen, A Brown, P Lampertico, J Schollmeyer, F Zoulim, H Wedemeyer, M Sterneck, T Berg, C Sarrazin, M Lutgehetmann, P Buggisch. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56(3): 520–526
https://doi.org/10.1016/j.jhep.2011.09.018
pmid: 22037226
|
45 |
W Chotiyaputta, C Peterson, FA Ditah, D Goodwin, AS Lok. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011; 54(1): 12–18
https://doi.org/10.1016/j.jhep.2010.06.016
pmid: 20888661
|
46 |
E Domingo. Viruses at the edge of adaptation. Virology 2000; 270(2): 251–253
https://doi.org/10.1006/viro.2000.0320
pmid: 10792982
|
47 |
C Rodriguez, S Chevaliez, P Bensadoun, JM Pawlotsky. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology 2013; 58(3): 890–901
https://doi.org/10.1002/hep.26383
pmid: 23505208
|
48 |
SW Ma, X Huang, YY Li, LB Tang, XF Sun, XT Jiang, YX Zhang, J Sun, ZH Liu, WG Abbott, YH Dong, NV Naoumov, JL Hou. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol 2012; 56(4): 775–781
https://doi.org/10.1016/j.jhep.2011.10.020
pmid: 22173154
|
49 |
Y Li, S Ma, L Tang, Y Li, W Wang, X Huang, Q Lai, M Zhang, J Sun, CK Li, WG Abbott, NV Naoumov, Y Zhang, J Hou. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. Hepatology 2013; 58(4): 1277–1286
https://doi.org/10.1002/hep.26489
pmid: 23703545
|
50 |
VW Wong, HL Chan. Transient elastography. J Gastroenterol Hepatol 2010; 25(11): 1726–1731
https://doi.org/10.1111/j.1440-1746.2010.06437.x
pmid: 21039833
|
51 |
HL Chan, GL Wong, PC Choi, AW Chan, AM Chim, KK Yiu, FK Chan, JJ Sung, VW Wong. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16(1): 36–44
https://doi.org/10.1111/j.1365-2893.2008.01037.x
pmid: 18673426
|
52 |
YP Chen, XE Liang, L Dai, Q Zhang, J Peng, YF Zhu, WQ Wen, HL Chan, JL Hou. Improving transient elastography performance for detecting hepatitis B cirrhosis. Dig Liver Dis 2012; 44(1): 61–66
https://doi.org/10.1016/j.dld.2011.08.004
pmid: 21907650
|
53 |
YP Chen, Q Zhang, L Dai, XE Liang, J Peng, JL Hou. Is transient elastography valuable for high-risk esophageal varices prediction in patients with hepatitis-B-related cirrhosis? J Gastroenterol Hepatol 2012; 27(3): 533–539
https://doi.org/10.1111/j.1440-1746.2011.06889.x
pmid: 21871027
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|